COMPANY RESEARCHOn 2026-05-01, FDA approved vepdegestrant for certain ESR1-mutated ER+/HER2- advanced breast cancers. In August, the company reported completion of a global license to Rigel and expected future data from three Phase 1 programs.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
On 2026-05-01, FDA approved vepdegestrant for certain ESR1-mutated ER+/HER2- advanced breast cancers. In August, the company reported completion of a global license to Rigel and expected future data from three Phase 1 programs.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| vepdegestrant（VEPPANU） | ER / BCL6 / LRRK2 · ESR1-mutated ER+/HER2− advanced or metastatic breast cancer progressing after at least one line of endocrine therapy (United States) | Approved | Regulatory validation limited to the approved jurisdiction / indication |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Arvinas announced an ASH poster on preliminary Phase 1 findings for oral BCL6 degrader ARV-393, also called zaloblideg, in relapsed or refractory non-Hodgkin lymphoma. The December 14 presentation will cover safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in T-cell lymphomas. The announcement itself does not provide numerical response results.
Arvinas said it will prioritize a Phase 1b study of its LRRK2 degrader ARV-102 in progressive supranuclear palsy in the European Union and United Kingdom. Trial applications and regulatory authorization remain pending. The company continues discussions with US and Japanese regulators, while the US investigational new drug application remains on hold.
Arvinas presented final Phase 1 findings for its brain-penetrant LRRK2 degrader ARV-102 in 24 patients with Parkinson’s disease treated for 28 days. Exploratory changes in eye movement measurements correlated with reductions in cerebrospinal fluid LRRK2 and changes in pathway biomarkers. The trial was not designed to establish clinical efficacy or effects on disease progression.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
Evommune licensed EVO570, formerly HC118, from Hinova for development and commercialization outside Greater China. Upfront consideration totals $30 million: $20 million cash and $10 million in pre-funded warrants. Additional development, regulatory, and commercial milestones could reach approximately $1.1 billion, plus royalties. Phase 1 was expected to begin shortly; the announcement does not establish human efficacy.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.